50545-37-4

Basic information

• Product Name: 3,4-DIHYDROXY-2-NITROBENZALDEHYDE
• Synonyms: 3,4-DIHYDROXY-2-NITROBENZALDEHYDE;Benzaldehyde, 3,4-dihydroxy-2-nitro-
• CAS NO: 50545-37-4
• Molecular Formula: C₇H₅NO₅
• Molecular Weight: 183.12
• Product Categories: Aromatic Aldehydes & Derivatives (substituted)
• Mol File: 50545-37-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Amber Vial, Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 3,4-DIHYDROXY-2-NITROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIHYDROXY-2-NITROBENZALDEHYDE(50545-37-4)
• EPA Substance Registry System: 3,4-DIHYDROXY-2-NITROBENZALDEHYDE(50545-37-4)

Safety Data

• Hazardous Substances Data: 50545-37-4(Hazardous Substances Data)

Upstream product

• 2450-26-2 2-nitrovanillin 
• 621-59-0 isovanillin 
• 6284-92-0 3-hydroxy-4-methoxy-2-nitrobenzaldehyde 
• 121-33-5 vanillin 
• 881-68-5 vanillin acetate 
• 2698-69-3 4-formyl-2-methoxy-3-nitrophenyl acetate 

Downstream Products

• 1103519-66-9 C₁₇H₁₅NO₆ 
• 50545-38-5 3,4-Di(benzyloxy)-2-nitrobenzaldehyd 
• 132277-38-4 4-[1,3]Dioxolan-2-yl-3-nitro-benzene-1,2-diol 
• 132277-42-0 7-[1,3]Dioxolan-2-yl-2,2-dimethyl-6-nitro-3-phenylselanyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine 
• 132277-40-8 2,2-Dimethyl-6-nitro-3-phenylselanyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-carbaldehyde 
• 132302-22-8 2-(3,3-Dimethyl-oxiranylmethoxy)-4-[1,3]dioxolan-2-yl-3-nitro-phenol 

Relevant articles and documents

Class of large ring heterocyclic compound restraining HCV and manufacturing and uses thereof

The invention relates to a class of compounds that inhibit HCV. The compounds are represented by Formula A. The invention also relates to preparation and pharmaceutical use of the compounds.

Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines

Forty caffeate analogues were synthesized via a convenient method starting from vanillin with moderate to good yields. The testing of biological activity of these compounds against HIV-1 integrase indicates that four compounds: bornyl caffeate, bornyl 2-nitrocaffeate, 5-nitrocaffeic acid and 5-nitrocaffeic acid phenethyl ester (5-nitroCAPE) possess a good HIV integrase inhibitory activity, IC50 19.9, 26.8, 25.0 and 13.5 μM, respectively. Twelve caffeate analogues were tested by MTT assay on growth of human hepatocellular carcinoma BEL-7404, human breast MCF-7 adenocarcinoma, human lung A549 adenocarcinoma and human gastric cancer BCG823 cell lines, respectively. And the best result is IC50 5.5 μM for CAPE against BEL-7404.